1. Scrip
  2. >>Archive

Profile: Lupin siblings on dinner table chats and not emulating Teva

 
• By Anju Ghangurde

This C-suite interview was quite different. It was one filled with plenty of sis-bro banter and peals of laughter amid all the serious talk on where India's third largest pharmaceutical company by sales sees itself by around 2020 and how it does not intend to emulate Teva, whose business model some peers look up to.

This C-suite interview was quite different. It was one filled with plenty of sis-bro banter and peals of laughter amid all the serious talk on where India's third largest pharmaceutical company by sales sees itself by around 2020 and how it does not intend to emulate Teva, whose business model some peers look up to.

In a candid interaction with Scrip as part of our ongoing executive profile series, the Lupin siblings – CEO Vinita...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Scrip

China Signals Restarting IPOs For Unprofitable Biotechs

 
• By Dexter Jie Yan

The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

 
• By Mandy Jackson, Joseph Haas, and Sarah Karlin-Smith

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.